Stock Under $10 with 50-100% upside potential - 14 Days FREE!

New Hope For Patients With Spinal Cord Injuries

ROSEMONT, Ill., Jan. 28, 2013 /PRNewswire-USNewswire/ -- Currently there is no effective treatment used in clinical practice for patients with an injured spinal cord.  However, a group of orthopaedic scientists have recently discovered that the administration of microRNA-210 could be an effective treatment for an injured spinal cord by promoting regeneration following injury.

(Logo: http://photos.prnewswire.com/prnh/20130122/MM45506LOGO)

Previously, microRNA-210 has been studied as an effective treatment for cancer and other diseases.  Scientists noted that there was an absence of this particular gene in cancerous tumors, but it was found in abundance in healthy tissue. By delivering what was missing directly to the diseased tumor, scientists were able to stop the progression of the disease.  Other scientists, however, noted that microRNA has the possibility to actually promote the growth of certain cancers.

Dr. Satoshi Ujigo from Hiroshima University in Japan and his colleagues applied this same theory to injured spinal cords hoping for similar results.  His work was recently presented at the Orthopaedic Research Society's (ORS) 2013 Annual Meeting in San Antonio, Texas this January.

Dr. Ujigo and his colleagues administrated miR-210 to a group of mice directly at the sight of the injured spinal cord.  These mice, as well as those in a control group, were studied and evaluated using the Basso Mouse Scale (BMS) as well as other methods of evaluation.  Seven days after injury, mice in the MiR-210 group could lift their trunks.  The mice in the control group were unable to support their body weight with their hind limbs.  In addition, the BMS scores for locomotion with the miR-210 group were significantly higher than in the control group at five days or later.

"Micro RNA-210 is one of the candidates for promoting spinal cord repair," Dr. Ujigo stated. "We are going to explore other candidates and to establish the best combination of micro RNAs for the effective treatment."

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
TRY IT FREE

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Dividend Stock Advisor
TRY IT FREE
New! $49.95/yr

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREE

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Real Money
TRY IT FREE

24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.

Product Features:
  • Jim Cramer + 20 Wall Street pros
  • Intraday commentary & news
  • Real-time trading forum
  • Actionable trade ideas
Real Money Pro
TRY IT FREE

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass + 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
TRY IT FREE

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 15,247.93 -46.57 -0.30%
NASDAQ 3,441.00 -18.42 -0.53%
S&P 500 1,641.37 -9.14 -0.55%
US 10 Yr 2.000% -0.023

Brokerage Partners

Advertising Partners
Special Features

Free Newsletters from TheStreet

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

We respect your privacy. Manage Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs